{"id":"locapred","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin atrophy"},{"rate":null,"effect":"Telangiectasia"},{"rate":null,"effect":"Striae"},{"rate":null,"effect":"Local irritation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a corticosteroid, Locapred works by binding to glucocorticoid receptors in skin cells, suppressing inflammatory cytokine production and reducing immune cell infiltration. This leads to decreased erythema, pruritus, and other inflammatory manifestations in dermatological conditions. The topical formulation allows localized delivery while minimizing systemic exposure.","oneSentence":"Locapred is a topical corticosteroid that reduces inflammation and immune response in localized skin conditions.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:19:19.185Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory skin conditions (specific indication in Phase 3 development unclear from available data)"}]},"trialDetails":[{"nctId":"NCT03437005","phase":"PHASE1","title":"Alternation in the Human Microbiome With Commonly Used Topical Medications","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2013-01-28","conditions":"Healthy","enrollment":24},{"nctId":"NCT07295678","phase":"NA","title":"URGO FilmoCream Eczema + Dermocorticoids in Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"CEN Biotech","startDate":"2026-01-05","conditions":"Atopic Dermatitis","enrollment":44},{"nctId":"NCT02624544","phase":"PHASE4","title":"Proton Pump Inhibitors Use in Patients With Psoriasis","status":"WITHDRAWN","sponsor":"EMS","startDate":"2016-01","conditions":"Psoriasis","enrollment":""},{"nctId":"NCT03386032","phase":"PHASE3","title":"8-Week Atopic Dermatitis (AD) Treatment Study","status":"COMPLETED","sponsor":"Procter and Gamble","startDate":"2017-11-27","conditions":"Atopic Dermatitis Eczema","enrollment":65},{"nctId":"NCT03758365","phase":"PHASE1","title":"Evaluation of the Vasoconstriction Properties of MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2018-11-05","conditions":"Vasoconstriction","enrollment":36},{"nctId":"NCT00690833","phase":"PHASE4","title":"Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis","status":"COMPLETED","sponsor":"Wake Forest University","startDate":"2007-08","conditions":"Atopic Dermatitis","enrollment":41},{"nctId":"NCT00828412","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis","status":"COMPLETED","sponsor":"Promius Pharma, LLC","startDate":"2009-03","conditions":"Atopic Dermatitis","enrollment":100},{"nctId":"NCT02732314","phase":"PHASE4","title":"Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis","status":"COMPLETED","sponsor":"Procter & Gamble Beauty","startDate":"2016-03","conditions":"Dermatitis, Atopic, Eczema","enrollment":53},{"nctId":"NCT02286700","phase":"PHASE3","title":"Skin Effects of a Topical Amino Acid Moisturizing Cream and Desonide in Atopic Dermatitis","status":"UNKNOWN","sponsor":"NeoStrata Company, Inc.","startDate":"2014-11","conditions":"Dermatitis, Atopic, Eczema","enrollment":42},{"nctId":"NCT01779258","phase":"PHASE3","title":"Emollients in the Management of Atopic Dermatitis","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2013-02","conditions":"Atopic Dermatitis","enrollment":347},{"nctId":"NCT01935310","phase":"NA","title":"Photoaging Treatment With Imiquimod","status":"COMPLETED","sponsor":"CES University","startDate":"2010-07","conditions":"Photoaging","enrollment":17},{"nctId":"NCT01467362","phase":"PHASE3","title":"Efficacy Emollient on Xerosis in Children With Atopic Dermatitis","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2011-11","conditions":"Atopic Dermatitis","enrollment":251},{"nctId":"NCT01542138","phase":"PHASE4","title":"Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation","status":"COMPLETED","sponsor":"Universidad Autonoma de San Luis Potosí","startDate":"2011-07","conditions":"Hyperpigmentation","enrollment":28}],"_emaApprovals":[],"_faersSignals":[{"count":15,"reaction":"DRUG INEFFECTIVE"},{"count":12,"reaction":"CUTANEOUS T-CELL LYMPHOMA"},{"count":11,"reaction":"PSORIASIS"},{"count":7,"reaction":"PRURITUS"},{"count":7,"reaction":"RECTAL HAEMORRHAGE"},{"count":6,"reaction":"ADENOCARCINOMA OF COLON"},{"count":6,"reaction":"DERMATITIS EXFOLIATIVE GENERALISED"},{"count":5,"reaction":"OFF LABEL USE"},{"count":5,"reaction":"PYREXIA"},{"count":5,"reaction":"TOOTH ABSCESS"}],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Locapred@","genericName":"Locapred@","companyName":"Pierre Fabre Medicament","companyId":"pierre-fabre-medicament","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Locapred is a topical corticosteroid that reduces inflammation and immune response in localized skin conditions. Used for Inflammatory skin conditions (specific indication in Phase 3 development unclear from available data).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}